Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of Azithromycin Oleogel in Healthy Adults
NCT05796362Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azithromycin in infectious disease (3 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Azithromycin bioavailability via pharmacokinetics up to 10 weeks and Initial Azithromycin Oleogel Safety Evaluation up to 10 weeks. Started Aug 2024; status: completed.
02
Drugs
azithromycin
03
Conditions
infectious disease
Beyond the preview
Go deeper on NCT05796362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796362.